Gold Standard Phantoms, a UCLB spinout company which is globally known for developing, marketing, and selling calibration services for Quantitative Medical Imaging, has developed a revolutionary solution to improve cancer diagnosis through Magnetic Resonance Imaging (MRI).
MRI scanners produce detailed images that must be interpreted by qualified radiologists, and
every scanner is slightly different, which can lead to misdiagnosis. To address this issue, radiolo-
gists need a means to calibrate scanners so that the images produced remain consistent across
scanners and time. Gold Standard Phantoms has developed CARE™, a state-of-the-art health-
care solution based on an advanced embedded phantom scanned with the patient, combined
with a traceable calibration software solution.
The PREDICT project, aimed at enhancing prostate cancer diagnosis using calibration technol-
ogy, will develop the CARE™ phantom to market readiness, funded by a €1.6m grant from
Horizon Europe’s EIC Accelerator programme.
Founded in 2014, Gold Standard Phantoms is a spinout arising from research at the UCL Institute of Neurology. The spinout has received guidance from UCLB, throughout its commercial journey.
UCLB’s Senior Business Manager Derek Reay, said: “It is great to see a UCLB spinout company receiving a Horizon Europe grant, particularly for prostate cancer where early detection is essential. PREDICT builds upon a range of MRI phantoms that have been developed and brought to market by Gold Standard Phantoms (GSP). We look forward to supporting GSP in the development and commercialisation of this latest MRI phantom.”